Atrys Health S A : Preview of Results financial year 2022. (EN)

Preview of Results financial year 2022

March 2023

Warning / Disclaimer and Cautionary Statements

This document and the results conference call (including the Q&A) may contain forward-looking statements and information (hereinafter referred to as "Statements") relating to ATRYS HEALTH, S.A. or the ATRYS Group (hereinafter referred to as "ATRYS", the "Company" or the "Group"). These statements may include financial projections and estimates with assumptions, statements regarding plans, objectives, and expectations that may relate to various matters, including, but not limited to, the customer base and its evolution, the growth of the various lines of business, market share, the results of the company and other aspects relating to the activity and situation of the company.

The forward-looking statements or forecasts contained in this document may be identified, in certain cases, by the use of words such as "expects", "anticipates", "intends", "believes" or similar language, or their corresponding negative form, or by the predictive nature of matters relating to strategies or plans or intentions. These forward-looking statements or forecasts reflect the views of ATRYS with respect to future events and are not, by their nature, guarantees of future performance and are subject to risks and uncertainties that could cause actual developments and results to differ materially from those expressed in such intentions, expectations or forecasts. Such risks and uncertainties include those identified in the documents with more complete information filed by ATRYS with the various supervisory bodies of the securities markets on which its shares are listed, and in particular with the Spanish Securities Market Commission (CNMV).

Except to the extent required by applicable law, ATRYS undertakes no obligation to publicly update the outcome of any revisions it may make to these statements to conform to events or circumstances after the date hereof, including, without limitation, changes in the Company's business, business development strategy or any other circumstances that may arise. This document may contain summary financial information, non-GAAP or unaudited information. The information contained herein should be read as a whole and is subject to all publicly available information about the Company, including, where applicable, other documents issued by the Company containing more complete information.

Finally, it is noted that neither this document nor anything contained herein constitutes an offer to buy, sell or exchange, or a solicitation of an offer to buy, sell or exchange any securities, or a recommendation or advice in respect of any securities.

Company developments

In the last 5 years ATRYS has established itself as a global consolidator aggregating 17 companies with the capacity to lead in the precision medicine and prevention segments.

First B2B tele-diagnostic company in Spanish with a leading position in Spain, Chile and Colombia.

Market leader in private oncology treatments in Spain.

Third largest health preventive company by market share in Spain.

With a relevant position in the diagnosis of Nuclear Medicine in Spain and Portugal.

Endowed with Corporate lean structure to drive growth and meet financial reporting requirements and ESG standards

211

CAGR

165

Pro forma turnover

+89,9%

					45		47
				21		36		Adj.
5	7	11		13			proforma
	7				EBITDA
							+90,0%
2016	2017	2018	2019	2020	2021	2022

3

Company developments

2022 highlights

Corporate

Trading at Continuos Market (BME) since February 2023

Corporate rating upgrade from BB- to BB in July 2022 (EthiFinance Rating).

Obtained ESG Risk 22.0 rating in December 2023 (Sustainanalytics Rating).

Sale 24.9% Conversia

• Transparency and increased visibility
• Access to a wider capital market
• Access to Qualified Investor
• Growth with improved solvency.
• Atrys improves its ESG position relative to its five industry peers by capitalisation.
• The score reflects the level of ESG management and assesses the strength of the company's ESG programmes, practices and policies.
• Partial "monetisation" of non-strategic asset by incorporating a financial partner to enhance value creation.

Company developments

2022 highlights

SIMM

• Allows to start diagnostic nuclear medicine activity in Spain
• More than 40,000 M.N. tests per year

M&A

Bienzobas

• It allows us to position ourselves as the leading company in terms of market share in medical oncology in Spain.
• Addition of +70 oncologists

• Presence in +45 hospitals reinforcing oncology patient referral agreements
• Provider of oncology patients for clinical trials

Initia

Chilerad / Chaxa

• It enables the initiation of clinical trials in medical oncology:
• • Reducing the cost of treatment.
  • Attracting and retaining talent in oncology.
  • Access to state-of-the-art treatments.

• It reinforces Atrys' position as a	• 90% market share
leading company in tele-radiology
in Chile.		5